Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.41 |
| ▸ | GLS | O94925 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5184187 | 1.00 | RIPK1 (0.41) | RIPK1GLSRAB9ANPC1F2 | |
| SCHEMBL583751 | 1.00 | RIPK1 (0.41) | RIPK1GLSRAB9ANPC1F2 | |
| SCHEMBL583080 | 0.87 | RIPK1 (0.41) | RIPK1GLSBDKRB1HTTMEN1 | |
| SCHEMBL583615 | 0.87 | RIPK1 (0.41) | RIPK1GLSBDKRB1HTTMEN1 | |
| SCHEMBL586952 | 0.87 | RIPK1 (0.41) | RIPK1GLSBDKRB1HTTMEN1 | |
| SCHEMBL582344 | 0.85 | CETP (0.43) | RIPK1RAB9ANPC1F2KDM4E | |
| SCHEMBL5512877 | 0.85 | CETP (0.43) | RIPK1RAB9ANPC1F2KDM4E | |
| SCHEMBL5516583 | 0.85 | CETP (0.43) | RIPK1RAB9ANPC1F2KDM4E | |
| SCHEMBL583522 | 0.83 | CETP (0.38) | RIPK1RAB9ANPC1F2KDM4E | |
| SCHEMBL582609 | 0.83 | CETP (0.38) | RIPK1RAB9ANPC1F2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1755572-B1 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2012-02-15 | — | — | EP | claimed |
| JP-2008501800-A | — | — | 2008-01-24 | — | — | JP | claimed |
| US-7268153-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-09-11 | — | — | US | claimed |
| CN-1976902-A | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO INC (US) | 2007-06-06 | — | — | CN | claimed |
| EP-1755572-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005120477-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | claimed |
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-12-15 | — | — | US | claimed |
| EP-1755572-B1 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2012-02-15 | — | — | EP | disclosed |
| US-7763659-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7629367-B2 | Tissue-selective androgen receptor modulators (SARMs); male hypogonadism, prostate cancer, benign prostate hyperplasia, sarcopenia, rheumatoid arthritis and osteoarthritis; N-((5-cyclopropyl-2-fluoropyridin-3-yl)methyl)-2-phenylbutanamide for example | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-09-27 | — | — | US | disclosed |
| US-7268153-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-09-11 | — | — | US | disclosed |
| CN-1976902-A | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO INC (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1755572-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120477-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | SHBG, AR, BRCA1 | RIPK1 2537/4885GLS 820/4885RAB9A 3925/4885 |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | SHBG, AR, BRCA1 | RIPK1 2537/4885GLS 820/4885RAB9A 3925/4885 |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | RIPK1 2512/4885GLS 953/4885RAB9A 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.